Advertisement
UK markets close in 7 hours 52 minutes
  • FTSE 100

    8,137.16
    +15.92 (+0.20%)
     
  • FTSE 250

    19,931.82
    +5.23 (+0.03%)
     
  • AIM

    766.17
    +1.19 (+0.16%)
     
  • GBP/EUR

    1.1687
    +0.0003 (+0.03%)
     
  • GBP/USD

    1.2537
    +0.0014 (+0.11%)
     
  • Bitcoin GBP

    45,982.37
    +467.91 (+1.03%)
     
  • CMC Crypto 200

    1,265.77
    -4.97 (-0.39%)
     
  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     
  • DOW

    37,903.29
    +87.37 (+0.23%)
     
  • CRUDE OIL

    79.48
    +0.48 (+0.61%)
     
  • GOLD FUTURES

    2,320.60
    +9.60 (+0.42%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • HANG SENG

    18,179.29
    +416.26 (+2.34%)
     
  • DAX

    17,920.99
    -11.18 (-0.06%)
     
  • CAC 40

    7,921.61
    -63.32 (-0.79%)
     

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

CHICAGO, April 02, 2024--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 11:00 am Eastern Time. To access the presentation, please visit "Events" on the investor relations page of the Company’s website at www.xerispharma.com.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, supporting long-term product development and commercial success.

ADVERTISEMENT

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240402611352/en/

Contacts

Investor Contact

Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com